key: cord-0996311-yj7pd6qy
authors: Garrido, Isabel; Liberal, Rodrigo; Macedo, Guilherme
title: Letter: liver disease and COVID‐19—not the perfect storm. Authors' reply”
date: 2020-07-13
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.15886
sha: 799aae9b19ac6bfb629be909b48610428ccd9daa
doc_id: 996311
cord_uid: yj7pd6qy

LINKED CONTENT This article is linked to Garrido et al and Nathwani et al papers. To view these articles, visit https://doi.org/10.1111/apt.15813 and https://doi.org/10.1111/apt.15872.

Dear Editors,

We read with great interest the letter by Nathwani et al 1 , commenting on our article on COVID-19 and liver disease 2 . They reported their experience in managing abnormal liver function tests during SARS-CoV-2 infection and the impact of COVID-19 in patients with underlying chronic liver disease. The authors concluded that mild serum elevations of aminotransferases were associated with more severe disease but not increased mortality. Additionally, they also reported that cirrhosis predisposes to increase in length of stay, although the overall mortality was similar to those without liver disease.

We agree that patients with cirrhosis would be of major concerns because of their immune dysfunction, resulting in a high risk of infection, prolonged hospitalisations and worse outcomes. However, in the series reported by Nathwani et al, liver cirrhosis did not predispose to increase in mortality, which is different from what has been reported in other recent publications. It should be noted that whether pharmacological therapy was used during hospitalisation was not reported; for example targeted anti-viral therapy, which is known to influence the outcomes of cirrhotic patients. In addition, the cause of death, whether liver related or not, was also not reported.

A recent systematic review and meta-analysis showed an in- In conclusion, it is essential to make immediate contact after the appearance of signs or symptoms compatible with COVID-19 or decompensated cirrhosis for urgent referral and management.

Additionally, more intensive surveillance and individually tailored therapeutic approaches are needed for cirrhotic patients with SARS-CoV-2 infection. Further research identifying interventions to reduce poor outcomes in these patients is required.

The authors' declarations of personal and financial interests are unchanged from those in the original article. 2

This article is linked to Garrido There are several scoring systems like REACH-B and GAG-HCC to predict the risk of HCC in untreated CHB patients. 5 However, these scores were not determined which may lead to bias in results.

As suggested by the authors also, this being a single-centre retrospective study where most of the CHB patients were likely infected with genotype C (which is an independent risk factor for development of HCC); further studies in patients with a different ethnicity and HBV genotype are required before generalising the results.

Letter: liver disease and COVID-19 -not the perfect storm

Review article: Covid-19 and liver disease -what we know on 1st

Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry

Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study

COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care

The liver in times of COVID-19: What hepatologists should know